The effect of combined therapy on the properties of the vessel wall in patients at high risk of cardiovascular complications

Introduction. The evaluation of therapy effectiveness in patients at high risk of cardiovascular complications includes the evaluation of target organs condition. A complex approach means follow-up control of laboratory and instrumental data. Materials and methods. The study included 113 patients with hypertension and nonstenotic atherosclerosis of brachiocephalic arteries. All the patients received antihypertensive therapy and some received hypolipidemic drugs. Cholesterol and low density lipoproteins (LDL) levels, brachial and central blood pressure (BP), brachial-ankle and carotid-femoral pulse wave velocity (baPWV and cfPWV, respectively), augmentation index (AI) of fibrosis markers (C-terminal telopeptide from collagen I (CITP) and C-terminal terminal propeptide of pro-collagen I (PINP) were assessed at baseline, after 6 months and 12 months of treatment with fixed combination of amlodipine, lisinopril and rosuvastatin. Results. The conducted therapy was followed by lowering the LDL levels from 3.9 (3.1; 4.6) to 2 (1.8; 2.3) mmol/L (p<0.01), brachial systolic and diastolic BP levels from 127 (116; 139) to 123 (115; 131) mm Hg (p<0.01) and from 79 (72; 89) to 75 (70; 83) mm Hg (p<0.01) respectively, central systolic and diastolic BP levels from 126 (112; 137) to 120 (110; 124) mm Hg (p<0.01) and from 80 (75; 87) to 76 (70; 81) mm Hg (p<0.01) respectively; by decreasing arterial stiffness: baPWV from 13.6 (12.5; 15.9) to 12.9 (11.8; 14.3) m/s (p<0.01) and cfPWV from 11 (9; 12.2) to 9.4 (8.4; 10.2) m/s (p<0.01), AI decreased from 31 (25; 35) to 26 (21; 32); p<0.05. The arterial stiffness index calculated without BP levels (cardio-ankle vascular index) decreased from 7.2 (6.6; 8.3) to 7.0 (6.6; 7.9) m/s (p<0.05). Treatment with Ekvamer® resulted in PINP levels decreasing from 49.8 (33; 67) to 35 (21; 52) mg/dL (p<0.05) and CITP - from 0.44 (0.24-0.6) to 0.3 (0.18-0.46) mg/dL (p<0.05). No difference between initial and final PINP/CITP levels was observed. The dynamics of PINP levels was associated with aortal stiffness dynamics, cfPWV (r=0.5; p<0.05). Conclusion. Treatment with fixed combination of amlodipine, lisinopril and rosuvastatin resulted in reaching target levels of LDL, brachial and central BP, and arterial stiffness decrease in patients at high risk of cardiovascular complications. The cfPWV dynamics was inter-related with collagen synthesis marker PINP levels.

high risk of cardiovascular complications, hypertension, arterial stiffness, fibrosis, fixed combination

1. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all - cause mortality with arterial stiffness: a systematic review and meta - analysis. J Am Coll Cardiol 2010; 55 (13): 1318-27.

2. Nürnberger J. Hypertonie, pulswellengeschwindigkeit und Augmentations - Index: die bedeutung der arteriellen Gefäßfunktion in der Praxis. Nieren Hochdruckkrankheiten 2009; 38 (1): 1-11.

3. Díez J, Laviades C, Mayor G et al. Increased serum concentrations of procollagen peptides in essential hypertension: relation to cardiac alterations. Circulation 1995; 91: 1450-6.

4. Díez J, Panizo A, Gil M et al. Serum markers of collagen type I metabolism in spontaneously hypertensive rates: relation to myocardial fibrosis. Circulation 1996; 93: 1026-32.

5. Brilla C.G, Matsubara L, Weber K.T. Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril - mediated regression of myocardial fibrosis. Hypertension 1996; 28: 269-75.

6. Brilla C.G, Funck R.C, Rupp H. Lisinopril - mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-93.

7. Sun Y, Ratajska A, Weber K.T. Inhibition of angiotensin - converting enzyme and attenuation of myocardial fibrosis by lisinopril in rats receiving angiotensin II. J Lab Clin Med 1995; 126: 95-101.

8. Williams B, Lacy P.S, Thom S.M et al. Differential impact of blood pressure - lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-25.

9. Kang B.Y. Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine. J Cardiovasc Pharmacol 2009; 54 (4): 327-34.

10. Marin F, Pascual D.A, Roldan V et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 2006; 97 (1): 55-60.

11. Драпкина О., Палаткина Л., Зятенкова Е. Плейотропные эффекты статинов. Влияние на жесткость сосудов. Врач. 2012; 9: 5-9.

12. Yusuf S, Bosch J, Dagenais G et al, HOPE-3 Investigators. Cholesterol Lowering in Intermediate - Risk Persons without Cardiovascular Disease. N Engl J Med 2016; 374 (21): 2021-31.

13. Roman M.J, Devereux R.B, Kizer J.R et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong heart study. Hypertension 2007; 50: 197-203.

14. Vlachopoulos C, Aznaouridis K, O'Rourke M.F. Prediction of cardiovascular events and all - cause mortality with central haemodynamics: a systematic review and meta - analysis. Eur Heart 2010; 15: 1865-71.

15. Williams B, Lacy P.S, Thom S.M et al, CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT) Investigators, CAFЕ Steering Committee and Writing Committee. Differential impact of blood pressure - lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-25.

16. Орлова Я.А., Нуралиев Э.Ю., Яровая Е.Б. и др. Снижение артериальной ригидности ассоциировано с благоприятным прогнозом у мужчин с ИБС. Сердце. 2009; 8 (5): 261-5.

17. Guerin A.P, Blacher J, Pannier B et al. Impact of aortic stiffness attenuation on survival of patients in end - stage renal failure. Circulation 2001; 103 (7): 987-92.